Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Recruiting · NCT05430399 · Registry updated 2023-07-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2023-07-13 | NCT05430399 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Biostar Pharmaceuticals Co., Ltd. | 9 |
| Hunan Cancer Hospital | 66 |
| Sun Yat-sen University | 606 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hunan Cancer Hospital | Hunan | China | 1 |
| Shusen Wang | Guangzhou | China | 1 |